- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Reona Sakemura Discusses Barriers to the Success of CAR T-Cell Therapies
Toxicities like cytokine release syndrome, along with other factors, limit widespread use of CAR T-cell therapies, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Toxicities like cytokine release syndrome, along with other factors, limit widespread use of CAR T-cell therapies, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Transcript
What are some of the barriers that are limiting the success of CAR T-cell therapies?
So, the widespread use of CAR T-cell therapy is limited due to lingering toxicities such as cytokine release syndrome, CRS, or neurotoxicity. Also, another limiting factor is CAR T-cell dysfunction, such as the poor T-cell expansions or poor traffic into tumor size, which is led by the bidirectional interaction between the tumor cells into a micro environment.
As CAR T-cell therapies are being used more, how has management of cytokine release syndrome improved?
The current way to manage Cytokine Release Syndrome, neurotoxicity, is the use of IL-6 receptor blockade, along with steroids. Early this year, we published that the perfect use of germs is neutralizing antibodies to not only prevent CRS but also to prevent the neurotoxicity in our mouse model. We're currently expanding this to a phase 2 clinical trial.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges
June 4th 2025Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.
Read More
